Drug Profile
SER 190
Alternative Names: SER190; SER190DFULatest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator Serodus
- Class Skin disorder therapies
- Mechanism of Action Interleukin 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetic foot ulcer
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for preclinical development in Diabetic-foot-ulcer in Norway
- 18 Jul 2017 Preclinical trials in Diabetic foot ulcer in Norway before July 2017 (Serodus pipeline, July 2017)